Drug intelligence / Profile preview

PST-900

Development stage: Unknown
Lead developer: Pharmasum Therapeutics
Modality: Small Molecules

Overview

PST-900 is an investigational **small molecule** inhibitor of dual-specificity tyrosine-phosphorylation-regulated kinase 1A intended to modulate DYRK1A-driven biology. It was initially developed by Pharmasum Therapeutics as a targeted kinase inhibitor, but available information indicates that the program was **discontinued** before commercialization. Publicly available details on formulation, route, and disease-specific clinical development are limited.

Targets

DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)

Beyond the preview

Go deeper on PST-900.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PST-900.

Explore the full profile